Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH

Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH

Cancer-specific mutations can lead to peptides of unique sequence presented on MHC class I to CD8 T cells. These neoantigens can be potent tumour-rejection antigens, appear to be the driving force behind responsiveness to anti-CTLA-4 and anti-PD1/L1-based therapies and have been used to develop pers...

Full description

Bibliographic Details
Main Authors: Stephanie J. Crowley, Patrick T. Bruck, Md Aladdin Bhuiyan, Amelia Mitchell-Gears, Michael J. Walsh, Kevin Zhangxu, Lestat R. Ali, Hee-Jin Jeong, Jessica R. Ingram, David M. Knipe, Hidde L. Ploegh, Michael Dougan, Stephanie K. Dougan
Format: Article
Language:English
Published: The Royal Society 2020-02-01
Series:Open Biology
Subjects:
vhh
cancer vaccines
cytokines
cancer immunology
neoantigens
alpaca nanobodies
Online Access:https://royalsocietypublishing.org/doi/pdf/10.1098/rsob.190235

Internet

https://royalsocietypublishing.org/doi/pdf/10.1098/rsob.190235

Similar Items